Approval · Notice of Compliance 30296 · 2023
OBIZUR: Notice of Compliance 30296
Issued March 9, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30296
- Date
- March 9, 2023
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph and Labelling update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OBIZUR | Not yet assigned | — |
Medicinal ingredients
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) PORCINE SEQUENCE 500 UNIT per ML